STOCK TITAN

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

TG Therapeutics (NASDAQ: TGTX) has announced upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in Phoenix, Arizona from May 28-31, 2025. The presentations include three key studies:

1. A platform presentation on the relationship between serum immunoglobulin levels and infections during long-term ublituximab treatment by Dr. Bruce Cree

2. A poster on infusion tolerability from the ENAMOR real-world observational survey presented by Dr. Edward Fox

3. A poster updating safety and tolerability data of 30-minute ublituximab infusions from the ENHANCE study by Dr. John Foley

All presentations are scheduled for May 29, 2025, and the data will be made available on TG Therapeutics' website after the presentations.

TG Therapeutics (NASDAQ: TGTX) ha annunciato le prossime presentazioni che includeranno dati su BRIUMVI® (ublituximab-xiiy) durante il meeting annuale 2025 del Consortium of Multiple Sclerosis Centers (CMSC) a Phoenix, Arizona, dal 28 al 31 maggio 2025. Le presentazioni riguarderanno tre studi principali:

1. Una presentazione principale sulla correlazione tra i livelli sierici di immunoglobuline e le infezioni durante il trattamento a lungo termine con ublituximab, a cura del Dr. Bruce Cree

2. Un poster sulla tollerabilità dell'infusione basato sull'indagine osservazionale ENAMOR nel contesto reale, presentato dal Dr. Edward Fox

3. Un poster con aggiornamenti sui dati di sicurezza e tollerabilità delle infusioni di ublituximab da 30 minuti, derivati dallo studio ENHANCE, a cura del Dr. John Foley

Tutte le presentazioni sono previste per il 29 maggio 2025 e i dati saranno resi disponibili sul sito web di TG Therapeutics dopo le presentazioni.

TG Therapeutics (NASDAQ: TGTX) ha anunciado próximas presentaciones que incluirán datos de BRIUMVI® (ublituximab-xiiy) en la reunión anual 2025 del Consortium of Multiple Sclerosis Centers (CMSC) en Phoenix, Arizona, del 28 al 31 de mayo de 2025. Las presentaciones cubrirán tres estudios clave:

1. Una presentación principal sobre la relación entre los niveles séricos de inmunoglobulinas y las infecciones durante el tratamiento a largo plazo con ublituximab, presentada por el Dr. Bruce Cree

2. Un póster sobre la tolerabilidad de la infusión basado en la encuesta observacional en el mundo real ENAMOR, presentado por el Dr. Edward Fox

3. Un póster con actualización de datos de seguridad y tolerabilidad de infusiones de ublituximab de 30 minutos, del estudio ENHANCE, presentado por el Dr. John Foley

Todas las presentaciones están programadas para el 29 de mayo de 2025 y los datos estarán disponibles en el sitio web de TG Therapeutics después de las presentaciones.

TG Therapeutics (NASDAQ: TGTX)는 2025년 5월 28일부터 31일까지 애리조나주 피닉스에서 열리는 2025년 다발성 경화증 센터 컨소시엄(CMSC) 연례 회의에서 BRIUMVI® (우블리툭시맙-xiiy) 데이터 발표를 예정하고 있다고 발표했습니다. 발표 내용은 세 가지 주요 연구를 포함합니다:

1. 브루스 크리 박사가 장기 우블리툭시맙 치료 중 혈청 면역글로불린 수치와 감염 간의 관계에 대해 하는 플랫폼 발표

2. 에드워드 폭스 박사가 실제 관찰 조사인 ENAMOR 연구에서의 주입 내성에 관한 포스터 발표

3. 존 폴리 박사가 ENHANCE 연구에서 30분 우블리툭시맙 주입의 안전성과 내성 데이터를 업데이트한 포스터 발표

모든 발표는 2025년 5월 29일에 예정되어 있으며, 발표 후 TG Therapeutics 웹사이트에서 데이터가 공개될 예정입니다.

TG Therapeutics (NASDAQ : TGTX) a annoncé des présentations à venir présentant des données sur BRIUMVI® (ublituximab-xiiy) lors de la réunion annuelle 2025 du Consortium of Multiple Sclerosis Centers (CMSC) à Phoenix, Arizona, du 28 au 31 mai 2025. Les présentations incluent trois études clés :

1. Une présentation principale sur la relation entre les niveaux d'immunoglobulines sériques et les infections pendant le traitement à long terme par ublituximab, par le Dr Bruce Cree

2. Un poster sur la tolérabilité de la perfusion issu de l'enquête observationnelle en conditions réelles ENAMOR, présenté par le Dr Edward Fox

3. Un poster mettant à jour les données de sécurité et de tolérabilité des perfusions d'ublituximab de 30 minutes issues de l'étude ENHANCE, présenté par le Dr John Foley

Toutes les présentations sont prévues pour le 29 mai 2025 et les données seront mises à disposition sur le site web de TG Therapeutics après les présentations.

TG Therapeutics (NASDAQ: TGTX) hat angekündigt, dass beim Jahrestreffen 2025 des Consortium of Multiple Sclerosis Centers (CMSC) in Phoenix, Arizona, vom 28. bis 31. Mai 2025 Präsentationen mit Daten zu BRIUMVI® (ublituximab-xiiy) stattfinden werden. Die Präsentationen umfassen drei wichtige Studien:

1. Eine Hauptpräsentation über den Zusammenhang zwischen Serumimmunoglobulinspiegeln und Infektionen während der Langzeitbehandlung mit Ublituximab durch Dr. Bruce Cree

2. Ein Poster zur Verträglichkeit der Infusion aus der ENAMOR Real-World-Beobachtungsstudie, präsentiert von Dr. Edward Fox

3. Ein Poster mit aktualisierten Sicherheits- und Verträglichkeitsdaten zu 30-minütigen Ublituximab-Infusionen aus der ENHANCE-Studie von Dr. John Foley

Alle Präsentationen sind für den 29. Mai 2025 geplant, und die Daten werden nach den Präsentationen auf der Website von TG Therapeutics verfügbar sein.

Positive
  • None.
Negative
  • None.

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 28-31, 2025 in Phoenix, Arizona. Abstracts are now available online and can be accessed on the CMSC meeting website at www.mscare.org/2025. Details of the upcoming presentations are outlined below.

TG PRESENTATIONS:

Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis

  • Presentation Date/Time: Thurs. May 29, 4:40pm MST/7:40pm ET
  • Session: North 122 ABC
  • Abstract & Poster Number: Platform Presentation – PLA-B6
  • Presenting Author: Dr. Bruce Cree - Weill Institute for Neurosciences, University of California, San Francisco, CA

Poster Presentation Title: Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR)

  • Presentation Date/Time: Poster Session Thurs. May 29, 5:00 - 7:00 pm MST/8pm ET
  • Session: Disease Modifying Therapy - North Exhibit Hall C-E
  • Abstract & Poster Number: DMT08
  • Presenting Author: Dr. Edward Fox – TG Therapeutics - National Physician Liaison – VP, MS Global Operations

Poster Presentation Title: Safety and Tolerability of 30-Minute Ublituximab Infusions: Updates from the ENHANCE Study

  • Presentation Date/Time: Poster Session Thurs. May 29, 5:00 - 7:00 pm MST/8pm ET
  • Session: Disease Modifying Therapy - North Exhibit Hall C-E
  • Abstract & Poster Number: DMT18
  • Presenting Author: Dr. John Foley – Rocky Mountain Multiple Sclerosis, Salt Lake City, Utah

Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.

ABOUT THE ULTIMATE I & II PHASE 3 TRIALS
ULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or teriflunomide, the active comparator, given orally as a 14 mg daily dose with IV placebo administered on the same schedule as BRIUMVI. Both studies enrolled patients who had experienced at least one relapse in the previous year, two relapses in the previous two years, or had the presence of a T1 gadolinium (Gd)-enhancing lesion in the previous year. Patients were also required to have an Expanded Disability Status Scale (EDSS) score from 0 to 5.5 at baseline. The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries. These trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University. Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248).

ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.

BRIUMVI is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease.

A list of authorized specialty distributors can be found at www.briumvi.com.

IMPORTANT SAFETY INFORMATION
Contraindications: BRIUMVI is contraindicated in patients with:

  • Active Hepatitis B Virus infection
  • A history of life-threatening infusion reaction to BRIUMVI

WARNINGS AND PRECAUTIONS

Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization.

Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.

Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI- treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved.

Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.

Hepatitis B Virus (HBV) Reactivation: HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HB surface antigen (HBsAg) and anti-HB tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.

Progressive Multifocal Leukoencephalopathy (PML): Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies.

If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.

If PML is confirmed, treatment with BRIUMVI should be discontinued.

Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.

Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy: In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.

Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is recommended in females of reproductive potential prior to each infusion. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.

Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections.

Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit www.briumvi.com.

ABOUT BRIUMVI PATIENT SUPPORT
BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at www.briumvipatientsupport.com.

ABOUT MULTIPLE SCLEROSIS
Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing- remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately 85% are initially diagnosed with RRMS.1,2 The majority of people who are diagnosed with RRMS will eventually transition to SPMS, in which they experience steadily worsening disability over time. Worldwide, more than 2.3 million people have a diagnosis of MS.1

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward- looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.

Such forward looking statements include but are not limited to statements regarding the results of the ULTIMATE I & II Phase 3 studies, the ENHANCE Phase 3b study, and BRIUMVI as a treatment for relapsing forms of multiple sclerosis (RMS). Additional factors that could cause our actual results to differ materially include the following: the risk that the data from the ULTIMATE I & II or ENHANCE trials that we announce or publish may change, or the product profile of BRIUMVI may be impacted, as more data or additional endpoints are analyzed; the risk that data may emerge from future clinical studies or from adverse event reporting that may affect the safety and tolerability profile and commercial potential of BRIUMVI; the risk that any individual patient’s clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials such as ULTIMATE I and II; the risk that BRIUMVI will not be commercially successful; our ability to expand our commercial infrastructure, and successfully market and sell BRIUMVI in RMS; the Company’s reliance on third parties for manufacturing, distribution and supply, and a range of other support functions for our commercial and clinical products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements; the uncertainties inherent in research and development; and general political, economic and business conditions, including the risk that the ongoing COVID-19 pandemic could have on the safety profile of BRIUMVI and any of our other drug candidates as well as any government control measures associated with COVID-19 that could have an adverse impact on our research and development plans or commercialization efforts. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in our other filings with the U.S. Securities and Exchange Commission.

Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

1. MS Prevalence. National Multiple Sclerosis Society website: https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Datamonitor p.236.


FAQ

What data will TGTX present at the 2025 CMSC annual meeting?

TG Therapeutics will present three studies on BRIUMVI® (ublituximab-xiiy) including data on long-term immunoglobulin levels and infections, real-world infusion tolerability (ENAMOR survey), and safety of 30-minute infusions (ENHANCE study).

When and where is the 2025 CMSC annual meeting where TGTX will present?

The 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting will be held from May 28-31, 2025, in Phoenix, Arizona.

Who are the presenting authors for TGTX's BRIUMVI presentations at CMSC 2025?

The presenting authors are Dr. Bruce Cree from UCSF, Dr. Edward Fox from TG Therapeutics, and Dr. John Foley from Rocky Mountain Multiple Sclerosis.

Where can investors find TGTX's CMSC 2025 presentation data after the event?

The presentation data will be available on TG Therapeutics' website at www.tgtherapeutics.com/publications.cfm in the Publications page within the Pipeline section.
Tg Therapeutics Inc

NASDAQ:TGTX

TGTX Rankings

TGTX Latest News

TGTX Stock Data

5.63B
143.36M
9.42%
62.81%
16.52%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK